Decroo T - Search Results

1

Van Deun A, Decroo T. Van Deun A, et al. Among authors: decroo t. Clin Infect Dis. 2021 Jun 15;72(12):e1167-e1168. doi: 10.1093/cid/ciaa1874. Clin Infect Dis. 2021. PMID: 33341871 No abstract available.

2

Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.

Decroo T, Van Deun A, Lynen L. Decroo T, et al. J Antimicrob Chemother. 2018 Jun 1;73(6):1733-1734. doi: 10.1093/jac/dkx497. J Antimicrob Chemother. 2018. PMID: 29293989 No abstract available.

3

Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.

Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL. Van Deun A, et al. Among authors: decroo t. Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660. Int J Tuberc Lung Dis. 2018. PMID: 29471899 Review.

4

Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring.

Van Deun A, Aung KJM, Hossain MA, Salim MAH, Gumusboga M, de Jong BC, Decroo T. Van Deun A, et al. Among authors: decroo t. Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1450-1461. doi: 10.5588/ijtld.18.0158. Int J Tuberc Lung Dis. 2018. PMID: 30606317

5

Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.

Van Deun A, Decroo T, Kuaban C, Noeske J, Piubello A, Aung KJM, Rieder HL. Van Deun A, et al. Among authors: decroo t. Int J Tuberc Lung Dis. 2019 Sep 1;23(9):965-971. doi: 10.5588/ijtld.19.0053. Int J Tuberc Lung Dis. 2019. PMID: 31615602

6

World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.

Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY. Van Deun A, et al. Among authors: decroo t. Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15. Int J Antimicrob Agents. 2020. PMID: 31626907

7

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.

Trébucq A, Decroo T, Van Deun A, Piubello A, Chiang CY, Koura KG, Schwoebel V. Trébucq A, et al. Among authors: decroo t. J Clin Med. 2019 Dec 25;9(1):55. doi: 10.3390/jcm9010055. J Clin Med. 2019. PMID: 31881691 Free PMC article. Review.

8

Tuberculosis treatment: one-shot approach or cascade of regimens?

Decroo T, de Jong BC, Piubello A, Lynen L, Van Deun A. Decroo T, et al. Lancet Respir Med. 2020 Feb;8(2):e4-e5. doi: 10.1016/S2213-2600(19)30473-4. Lancet Respir Med. 2020. PMID: 32035067 No abstract available.

9

Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.

Piubello A, Souleymane MB, Hassane-Harouna S, Yacouba A, Lempens P, Assao-Neino MM, Maman-Lawan I, Attaher S, Moustapha B, Soumana A, Gagara-Issoufou A, Ortuño-Gutiérrez N, Roggi A, Gumusboga M, Hamidou-Harouna Z, Dockx J, Mamadou S, de Jong BC, Decroo T, Van Deun A. Piubello A, et al. Among authors: decroo t. Respir Med. 2020 Jan;161:105844. doi: 10.1016/j.rmed.2019.105844. Epub 2019 Nov 23. Respir Med. 2020. PMID: 32056722 Free article.

10

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.

Decroo T, de Jong BC, Piubello A, Souleymane MB, Lynen L, Van Deun A. Decroo T, et al. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1578-1579. doi: 10.1164/rccm.202001-0201LE. Am J Respir Crit Care Med. 2020. PMID: 32130864 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page